# US 2025/0084084 A1 · Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084084 A1
- Document ID: US20250084084A1
- Status: Published application
- Kind: A1
- Application number: 18/954,736
- Filed: 2024-11-21
- Published: 2025-03-13
- Earliest claimed: 2020-06-09
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Christopher Ryan BUTLER; Michelle Renee GARNSEY; Kevin Alexander OGILVIE; Jana POLIVKOVA; Matthew Forrest SAMMONS; Aaron Christopher SMITH; Qingyi Yang
- Web page: https://patentgrep.com/patent/US20250084084A1

## CPC

- C07D 471/20: Spiro-condensed systems
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Described herein is a crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one having a powder X-ray diffraction pattern comprising at least one characteristic peak, in terms of 2θ at a copper wavelength, selected from 8.7±0.2, 11.1±0.2, and 13.3±0.2.

## Claims

### Claim 1

A crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one having a powder X-ray diffraction pattern comprising at least one characteristic peak, in terms of 2θ at a copper wavelength, wherein the characteristic peak is selected from 8.7±0.2, 11.1±0.2, and 13.3±0.2.

### Claim 2 (depends on 1)

The crystalline form according to claim 1, comprising at least two of the characteristic peaks.

### Claim 3 (depends on 2)

The crystalline form according to claim 2, comprising the characteristic peaks 8.7±0.2 and 11.1±0.2.

### Claim 4 (depends on 1)

The crystalline form according to claim 1, comprising the characteristic peaks 8.7±0.2, 11.1±0.2, and 13.3±0.2.

### Claim 5 (depends on 4)

The crystalline form according to claim 4, having a powder X-ray diffraction pattern further comprising the characteristic peaks as shown in Table X1.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the crystalline form of claim 1, and at least one pharmaceutically acceptable excipient.

### Claim 7 (depends on 6)

A pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is administered orally.

### Claim 8 (depends on 6)

A pharmaceutical composition according to claim 6, wherein the dosage form of the pharmaceutical composition is a tablet, a solution, or a suspension.

### Claim 9 (depends on 8)

A pharmaceutical composition according to claim 8, wherein the dosage form of the pharmaceutical composition is the tablet.